<DOC>
	<DOCNO>NCT00434096</DOCNO>
	<brief_summary>The primary objective study assess efficacy SR141716 compare placebo body weight triglyceride change period 52 week . Secondary objective : - To evaluate effect SR141716 compare placebo period 52 week , HDL-cholesterol visceral fat area . - To evaluate safety SR141716 compare placebo period 104 week . - To evaluate pharmacokinetics SR141716 .</brief_summary>
	<brief_title>Japanese Study Rimonabant Obese Patients With Dyslipidemia ( VENUS )</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Rimonabant</mesh_term>
	<criteria>Body Mass Index ( BMI ) &gt; 25 kg/m² Visceral Fat Area ( VFA ) &gt; 100 cm² Triglycerides ( TG ) &gt; 150 mg/dL &lt; 700 mg/dL , and/or HDLcholesterol &lt; 40 mg/dL ( Dyslipidemia ) At least 1 criterion follow 2 comorbidities : Impaired Glucose Tolerance Type 2 diabetes Hypertension Patient secondary obesity . Patients receive diet therapy le 8 week start observation period . Patients whose body weight change variation ± 2kg screening period . Low compliance drug intake ( &lt; 80 % ) dietary instruction observation period . Patients type 1 diabetes . Patients primary hyperlipidemia ( i.e. , familial hypercholesterolemia , familial combine hyperlipidemia familial type III hyperlipidemia ) . Patients LDLcholesterol &gt; 190 mg/dL Weeks 8 4 . Patients secondary hypertension .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Obesity disease</keyword>
	<keyword>cannabinoid-1 receptor</keyword>
</DOC>